Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2019 OR ◻ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 | --- | --- | |----------------------------------------------------------------------------------------------------|-----------------------------------------------------| | | | | For the ...

Axsome Therapeutics, Inc. (NASDAQ:AXSM) Q4 2019 Earnings Conference Call March 12, 2020 8:00 AM ET Company Participants Mark Jacobson - COO Herriot Tabuteau - CEO Cedric O'Gorman - SVP of Clinical Development and Medical Affairs Dave Marek - Chief Commercial Officer Nick Pizzie - CFO Conference Call Participants Charles Duncan - Cantor Fitzgerald Ram Selvaraju - HC Yatin Suneja - Guggenheim Partners Marc Goodman - SVB Matt Kaplan - Ladenburg Bert Hazlett - BTIG Myles Minter - William Blair Operator Good mor ...

Axsome Therapeutics, Inc (NASDAQ:AXSM) Q3 2019 Earnings Conference Call November 7, 2019 8:00 AM ET Company Participants Mark Jacobson - SVP of Operations at Axsome Therapeutics Herriot Tabuteau - Chief Executive Officer Cedric O'Gorman - SVP of Clinical Development and Medical Affairs David Marek - Chief Commercial Officer Nick Pizzie - Chief Financial Officer Conference Call Participants Charles Duncan - Cantor Fitzgerald Yatin Suneja - Guggenheim Joon Lee - SunTrust Robinson Humphrey Robert Hazlett - BTI ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2019 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ________ to ________ Commission File Number 001-37635 AXSOME THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 45- ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2019 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ________ to ________ Commission File Number 001-37635 AXSOME THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 45-42419 ...